Amicus Therapeutics (FOLD) IPO Trades Higher
More News related to FOLD
- Amicus Therapeutics to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
- Amicus Therapeutics Appoints Margaret G. McGlynn, R.Ph., to Board of Directors
- Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
- Amicus Therapeutics Announces Third Quarter 2009 Financial Results Release Date
More News related to IPOs
- Kraton Performance Polymers (KRA) Sees IPO Price of $16-$18
- National Beef (NBP) Updates IPO Pricing Information
- Soleil Securities Maintains a 'Buy' on Las Vegas Sands (LVS); Comments on Sands China IPO
- AIG Closes Transaction with NY Fed, Clearing Way for ALICO Sale or IPO
The IPO Amicus Therapeutics (Nasdaq: FOLD) is open for trading. The stock is trading at $16.34 after pricing at $15.00, the middle of the expected $14.00-16.00 range.
Morgan Stanley & Co. Incorporated and Merrill Lynch & Co. served as joint book-runners for the offering, with J.P. Morgan Securities Inc., Lazard Capital Markets LLC, and Pacific Growth Equities, LLC acting as co-managers.
Amicus Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases.
Related Categories
IPOsStocks Mentioned
+0.26Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
